Imugene (ASX: IMU) — Company Overview, News & Financial Data
Imugene is a clinical-stage immuno-oncology company developing T-cell receptor therapies and oncolytic virotherapies for cancer treatment.
Imugene
Imugene is a clinical-stage immuno-oncology biotechnology company focused on developing novel cancer therapies designed to harness the immune system to treat B-cell malignancies and solid tumors. The company's platform includes allogeneic chimeric antigen receptor T-cell therapies, oncolytic viruses, and cancer immunotherapies. Its clinical pipeline features off-the-shelf cellular therapeutics such as azercabtagene zapreleucel, targeting CD19-expressing blood cancers, along with proprietary oncolytic virus technologies like CF33 and B-cell immunotherapy platforms. Imugene conducts clinical trials across novel targets to provide therapeutic options for patients with advanced or refractory cancers.
Snapshot
Operations
Products and/or services of Imugene
- Allogeneic Cell Therapies: Off-the-shelf cellular immunotherapy programs centered on azercabtagene zapreleucel targeting CD19 in Phase 1b clinical trials for B-cell malignancies and non-Hodgkin lymphoma to evaluate safety and clinical efficacy in patients.
- Oncolytic Virus Therapies: Engineered chimeric poxvirus platforms featuring VAXINIA and CHECKvacc constructs designed to selectively infect, replicate within, and lyse tumor cells while activating systematic antitumor immune responses across multiple solid tumor indications.
- B-Cell Immunotherapies: Active immunotherapeutic platforms including HER-Vaxx and PD1-Vaxx vaccine candidates engineered to stimulate the host immune system to generate polyclonal antibodies targeting specific cancer antigens such as HER2 and PD-1 pathways.
- Combination Tumor Platforms: Oncolytic virus technologies engineered to express CD19 targets on solid tumor cells, enabling CD19-directed CAR T cell therapies and targeted therapeutics to recognize and destroy previously untargetable solid tumor masses.
- Clinical Development Operations: Clinical trial management conducting Phase 1 and Phase 2 human trials across medical centers in Australia and North America to evaluate therapeutic safety, dosage escalation, and therapeutic efficacy across novel targets.
- Biopharmaceutical Licensing: Strategic licensing and collaborative research agreements for proprietary cell therapy and oncolytic virus platforms, supporting pre-clinical asset discovery, technology transfer, and commercialization pathways across global biopharmaceutical markets.
Imugene executive team
- Paul Edward-Alexander HopperExecutive Chairman
Latest news about Imugene
Imugene reports 71% response rate in trial
AustraliaImugene CEO steps down after 11 years
AustraliaImugene completes $11.1M share placement
AustraliaImugene records second complete clinical response
AustraliaImugene reports first complete trial patient response
AustraliaThe startup tax workaround quietly reshaping local venture capital networks
Australia
Recent announcements
What Imugene (IMU) has told the market, newest first.
- Notice of Annual General Meeting/Proxy Form
- Dr John Le Gall appointed Chief Medical Officer
- azer-cel BTKi Cohort Reports new Complete & Partial ResponsePrice sensitive
- Change of Director's Interest Notice - JD
Key financials
Reported results for Imugene, in AUD.
- Market cap
- 16.6M
- Revenue (TTM)
- 2.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -75M | -105.3M | |
| 4.4M | -70.9M | -69M | |
| 5M | -140.9M | -149.7M | |
| 11.8M | -51.3M | -37.9M |